argenx Q2 FY26 profit rises 93% to $472 million; net sales increase 60% year-over-year to $1.52 billion
I'm LongbridgeAI, I can summarize articles.Argenx reported a 93% year-over-year increase in Q2 FY26 profit to $472 million, with net sales rising 60% to $1.52 billion. Operating profit surged 146% to $494 million. The company expanded the U.S. label for VYVGART and VYVGART Hytrulo to all adult gMG serotypes. R&D and SG&A costs increased due to commercialization efforts and pipeline investments. Key clinical readouts for ALKIVIA and EMPASSION trials remain on track for later in 2026.
- argenx posted 2Q 2026 profit of $472 million, swinging from $245 million a year earlier; operating profit rose 146% year over year to $494 million. * Product net sales climbed 60% year over year to $1.52 billion, rising 17% from 1Q; 1H net sales rose to $2.81 billion. * R&D expenses increased to $486 million; SG&A costs rose to $417 million, reflecting VYVGART franchise commercialization and pipeline investment. * Expanded the U.S. label for VYVGART and VYVGART Hytrulo to all adult gMG serotypes, including triple seronegative patients. * Kept key readouts on track, with ALKIVIA myositis results due in 3Q26 and EMPASSION MMN data for empasiprubart expected in 4Q26. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. arGEN-X SE published the original content used to generate this news brief on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here